Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 10Completed 9Recruiting 6Unknown 4Withdrawn 1Suspended 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Neoplasms 12Leukemia, Myeloid, Acute 12Neoplasm Metastasis 9Melanoma 7Breast Neoplasms 7Prostatic Neoplasms 6Pancreatic Neoplasms 6Ovarian Neoplasms 6Colorectal Neoplasms 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Myelodysplastic Syndromes 5Lung Neoplasms 5Glioma 5Hematologic Neoplasms 4Glioblastoma 4Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Solid Tumors 3Small Cell Lung Carcinoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma 3Head and Neck Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Non-Small-Cell Lung 3Unspecified Adult Solid Tumor, Protocol Specific 2Solid Tumor 2Sarcoma 2Osteosarcoma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, B-Cell 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Suspended × Neoplasms by Histologic Type × Clear all
NCT03722186 2021-03-22

Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Suspended
128 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Neoplasms by Histologic Type, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡